

Table SI. Concurrent chemoradiotherapy and immunotherapy.	
Regimen	n (%)
Radiotherapy 60 Gy; carboplatin/cisplatin + pemetrexed; durvalumab	4 (3.0)
Radiotherapy 60 Gy; carboplatin/cisplatin + pemetrexed; sintilimab	18 (13.4)
Radiotherapy 60 Gy; carboplatin/cisplatin + pemetrexed; sugemalimab	11 (8.2)
Radiotherapy 66 Gy; cisplatin + etoposide; durvalumab	8 (6.0)
Radiotherapy 66 Gy; cisplatin + etoposide; sintilimab	58 (43.3)
Radiotherapy 66 Gy; cisplatin + etoposide; tislelizumab	21 (15.7)
Radiotherapy 66 Gy; cisplatin + etoposide; sugemalimab	14 (10.4)

Table SII. Relapse sites.	
Patterns of recurrence	n (%)
Locoregional relapse	78 (100.0)
Ipsilateral hemithorax	53 (67.9)
Regional lymph nodes	25 (32.1)
Distant metastasis	65 (100.0)
Contralateral lung	2 (3.1)
Brain	10 (15.4)
Bone	17 (26.2)
Distant lymph nodes	8 (12.3)
Suprarenal gland	3 (4.6)
Liver	3 (4.6)
Pleural cavity	4 (6.2)
Multiple sites	18 (27.7)

Table SIII. Post-relapse treatment modalities for patients with recurrence.		
Post-relapse treatment	Number of patients	Percentage (%)
Traditional Chinese medicine or palliative therapy	8	6.1
First-line therapy	123	93.9
Immunotherapy combined with chemotherapy	61	46.6
Immunotherapy combined with chemotherapy plus radiotherapy	61	46.6
Immunotherapy alone	1	0.8
Total relapsed patients	131	100.0